Todd Bauer headshot
TB

Todd W. Bauer

Professor
Unit: School of Medicine
Department: Department of Surgery
Office location and address
81 Hospital Dr
Charlottesville, Virginia 22903
Education
BA, Biology, University of Pennsylvania, Philadelphia, PA
BS, Economics, University of Pennsylvania, Philadelphia, PA
MD, Surgery, University of Pennsylvania, Philadelphia, PA
Biography

Todd W. Bauer, M.D. is an Assistant Professor of Surgery in the Division of Surgical Oncology at the University of Virginia. He received his undergraduate degree and M.D. from the University of Pennsylvania. He then completed his General Surgery residency and a post-doctoral research fellowship at the Hospital of the University of Pennsylvania. He then completed a fellowship in Surgical Oncology and a post-doctoral research fellowship at the University of Texas MD Anderson Cancer Center.

Dr. Bauer's clinical focus is in pancreatic and hepatobiliary cancers and soft tissue sarcoma. He leads a laboratory research program in pancreatic cancer. The current focus of his laboratory research is on the interaction between tumor cells and stromal fibroblasts and developing novel approaches to targeting the tumor microenvironment.  He has established a primary human xenograft model of pancreatic cancer with genetic and molecular characterization of tumors with the aim of deriving a personalized approach to therapy for pancreatic cancer.

Optimal control models of epithelial-mesenchymal transition for the design of pancreas cancer combination therapy
Source: U.S. NIH Cancer Institute
August 01, 2019 – July 31, 2024
MD-INMD-HO A randomized Multicenter Phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with MK-3475 (anti-PD1) to CRT alone in patients with resectable pancreatic cancer
Source: Merck Sharp & Dohme Corp.
December 19, 2014 – April 30, 2024
Virginia Kincaid Cancer Research Fund
Source: Virginia Kincaid Charitable Trust
October 01, 2005 – December 31, 2021
Implementation and Clinical Impact of a Next Generation Precision Oncology Platform
Source: Virginia Biosciences Health Research Corporation
May 01, 2019 – April 30, 2021
MD-INMD A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Source: NewLink Genetics Corporation
September 29, 2014 – September 29, 2018
MD-SURG Commercialization of a Translational Human Tumor Microenvironment System for Pharmaceutical Cancer Drug Discover and Development
Source: Virginia Biosciences Health Research Corporation
March 01, 2014 – September 30, 2016
Cancer Center Support Grant - Year 21
Source: U.S. NIH Cancer Institute
June 05, 2012 – January 31, 2016
Commonwealth Foundation for Cancer Research
Source: Commonwealth Cancer Foundation for Research
June 01, 2002 – December 31, 2015
ZielBio, http://itihealth.com/ https://zielbio.com/z-home